Document is current
Any future updates will be listed below
-
Authors
D’Alise, Anna Morena https://orcid.org/0000-0002-0763-6269
Willis, Jason
Duzagac, Fahriye
Hall, Michael J. https://orcid.org/0000-0003-4515-3409
Cruz-Correa, Marcia
Idos, Gregory E.
Thirumurthi, Selvi
Ballester, Veroushka
Leoni, Guido
Garzia, Irene https://orcid.org/0009-0008-3001-2674
Antonucci, Laura https://orcid.org/0000-0001-8965-2432
De Marco, Lorenzo
Micarelli, Elisa
Deng, Nan
Seclì, Laura
Gogov, Sven
Dong, Wenli
Jack Lee, J. https://orcid.org/0000-0001-5469-9214
Bowen, Charles M.
Vornik, Lana A.
Garcia-Gonzalez, Araceli
Reyes-Uribe, Laura
Richmond, Ellen
Umar, Asad
Brown, Powel H. https://orcid.org/0000-0002-3398-163X
Sinha, Krishna M.
Rodriguez, Luz Maria
Scarselli, Elisa https://orcid.org/0000-0002-5393-6713
Vilar, Eduardo https://orcid.org/0000-0001-6404-3761
- License Information
-
More Information
Article History
Received: 29 July 2025
Accepted: 12 December 2025
First Online: 16 January 2026
Competing interests
: E.V. has had a consulting or advisory role with Janssen Research and Development, Recursion Pharma, Nouscom, Abbvie, Moderna, Permanence Bio and Parabilis, has received research support from Janssen Research and Development and has equity in Permanence Bio. J.W. has had a consulting role with Healios H.K. and TME Therapeutics and has received research support from Amal Therapeutics. E.S. is Nouscom cofounder and employee and reports stock ownership. A.M.D. and S.G. are employees of Nouscom and report stock ownership. I.G., L.A., L.D.M., E.M. and L.S. are employees of Nouscom. M.C.C. has research contracts with BMS, Jannsen, MERCK, AstraZeneca, Abbvie, Huyabio, BeiGene, Natera, Exact Sciences, INCYTE, Astellas, Genentech, GenMab, Revolution Medicine and Pfizer. The remaining authors declare no competing interests.
